@inshatters1 RSRS

RSRS posts on X about $vktx, $ovid, $drug, $nvo the most. They currently have [--] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

• [--] Week [-----] +35%
• [--] Month [-----] -81%
• [--] Months [------] +2,474%
• [--] Year [------] +299%

Mentions: [--] #

Followers: [--] #

• [--] Week [--] +1.20%
• [--] Month [--] +1.20%
• [--] Months [--] +96%
• [--] Year [--] +1,367%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 22% finance 6% travel destinations 2% currencies 2% social networks 1% countries 1%

Social topic influence $vktx #39, $ovid 12%, $drug 10%, $nvo #132, $lly #73, $xene #9, $espr #6, market cap 4%, $catx #10, ceo 3%

Top accounts mentioned or mentioned by @seedy19tron @persimmonti @bioinvestor24 @biotech2k1 @adamfeuerstein @sharkbiotech @davidstehle @houndcl @smiuffy @andrearilli @masonat7 @financebully @espr @monacobiotech @avidresearch @annak4ever @amaymd @apexonco @cestlaviemacher @buffalo51766917

Top assets mentioned Viking Therapeutics, Inc (VKTX) Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Xenon Pharmaceuticals Inc (XENE) Viking Holdings Ltd (VIK) Metsera, Inc. (MTSR) Rapport Therapeutics, Inc. (RAPP) Synthetify (SNY) Pfizer, Inc. (PFE) Abivax SA (ABVX) NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Praxis Precision Medicines, Inc. (PRAX) Kymera Therapeutics, Inc. (KYMR) Wave Life Sciences Ltd. Ordinary Shares (WVE) PepGen Inc. (PEPG) Protagonist Therapeutics, Inc (PTGX) uniQure N.V. (QURE) Bristol-Myers Squibb Co (BMY) Johnson & Johnson (JNJ) Longboard Pharmaceuticals, Inc. (LBPH) Atai Life Sciences B.V. (ATAI) AbbVie Inc (ABBV) Revolution Medicines, Inc. (RVMD)

Top Social Posts

Top posts by engagements in the last [--] hours

"$NVO CEO: We have seen that especially within the field of obesity this acts a lot more as a consumer business than a traditional medication $VKTX https://www.fiercepharma.com/pharma/jpm26-novo-nordisk-ceo-reflects-curse-leader-company-looks-reassert-glp-1-footing $VKTX imo what the market is missing is that obesity drugs by $LLY & $NVO are now a massive consumer-driven market. In such markets the best products tend to win. Even more so in the wellness market. If VK2735 is indeed a superior product it will become market leader."
X Link 2026-01-14T21:01Z [--] followers, [---] engagements

"#SuperBowl the amount of people coming out with opinions and moralizing about what is un-American mm #BadBunny"
X Link 2026-02-09T17:31Z [--] followers, [--] engagements

"$vktx autoinjector ready to go (finally)"
X Link 2026-02-11T21:45Z [--] followers, [---] engagements

"$VKTX management keeps executing and delivering [----] will be here in the blink of an eye"
X Link 2026-02-11T21:26Z [--] followers, [---] engagements

"$VKTX MTSR was bought out for $10B I guess BL wanted at least double that as clinical trials expand and progress data matures and new programs (Amylin) come online value will surely appreciate"
X Link 2026-02-11T23:17Z [--] followers, [---] engagements

"$DRUG days away from bmb-101 epilepsy readout. $RAPP market cap $1.4B so IF PH2 hits DRUG imo will at a minimum meet that valuation (currently $600M market cap). Moreover companys developing broad portfolio of 5-HT2C agonists that may address many indications"
X Link 2026-01-02T22:08Z [--] followers, [---] engagements

"@seedy19tron $KYMR valuation $6B"
X Link 2026-02-10T21:34Z [--] followers, [---] engagements

"$CATX nice move on $SNY discontinuating competing radioligand (likely because of safety profile As highlighted by @ApexOnco). Funny and humbling that the catalyst is failure by competitor hopefully management can also deliver catalysts of their own"
X Link 2026-01-29T18:21Z [--] followers, [---] engagements

"$ESPR discovery that BA also locks into PPAR alpha benefits: burns fat and stops inflammation (explains why BA unlike statins reduces diabetes risk). This could be a huge catatalyst over next years. & why wouldnt $LLY $PFE $NVO be interested in BA as Obesity combo"
X Link 2026-02-01T14:26Z [--] followers, [---] engagements

"$ESPR new Jan [----] discovery that BA locks into PPAR alpha effectively / practically guarantees patent life for BA is extended to [----]. This is massive also given ANDAS (Sandoz still a holdout)"
X Link 2026-02-01T23:20Z [--] followers, [---] engagements

"$ESPR here the paper with the new MOA discovery regarding BA https://www.sciencedirect.com/science/article/pii/S1550413125005492via%3Dihub https://www.sciencedirect.com/science/article/pii/S1550413125005492via%3Dihub"
X Link 2026-02-01T23:51Z [--] followers, [---] engagements

"$VKTX $LLY dual agonist revenues keep going up while eating up $NVO market share. No surprise there: most people following the space predicted that much over two years ago this is also the reason why Viking will be a winner when ph3s read out: BIC potential + dual agonist"
X Link 2026-02-04T20:53Z [--] followers, [---] engagements

"$VKTX I added to my position these past 2-3 days (increased by 18%)"
X Link 2026-02-11T23:00Z [--] followers, [---] engagements

"$XENE slow execution so far (pushed back ph3 readout twice already) but highly encouraging OLE data. Given this if the ph3 hits and replicates ph2 results the drug will be huge commercial success. $XENE OLE data: 38% achieving one year seizure freedom quite impressive. This for DRE. Wonder if peak revenues will dwarf what most analysts predict https://t.co/LZcR0xnqKm $XENE OLE data: 38% achieving one year seizure freedom quite impressive. This for DRE. Wonder if peak revenues will dwarf what most analysts predict https://t.co/LZcR0xnqKm"
X Link 2026-02-11T23:27Z [--] followers, [---] engagements

"My top five positions are $espr $ovid $vktx $abvx $drug Other sizable positions $capr $nktr $catx $xene $wve $pepg"
X Link 2026-02-13T14:43Z [--] followers, [---] engagements

"@cestlaviemacher Yeah definitely discouraging to see. Could do much better and set better example considering the climate crisis"
X Link 2025-07-15T11:52Z [--] followers, [--] engagements

"@Buffalo51766917 Most for the study are below 80"
X Link 2025-07-24T21:32Z [--] followers, [--] engagements

"@adamfeuerstein He recently said that he was reminded that no biotech investor is immortal so I guess he dodged one there - rent-fee for eternity in his head would have be quite something"
X Link 2025-08-05T21:02Z [--] followers, [--] engagements

"#AI #Gemini pro is very frustrating: has trouble keeping tabs during long exchanges / threads often reshuffles the answers to earlier questions instead of answering the question. Also prone to conflating information & every answer it gives is long tedious repetitive-sounding"
X Link 2025-08-06T15:07Z [--] followers, [--] engagements

"#prasad #FDA latest https://www.politico.com/news/2025/08/14/rfk-trump-prasad-wiles-sarepta-loomer-maha-00508819 https://www.politico.com/news/2025/08/14/rfk-trump-prasad-wiles-sarepta-loomer-maha-00508819"
X Link 2025-08-14T12:20Z [--] followers, [--] engagements

"@sharkbiotech Love London and absolutely loved it when I lived there (Liverpool st bloomsbury) so many parks museums cycle lanes eateries markets amazing venues people from all over the world"
X Link 2025-08-18T20:34Z [--] followers, [--] engagements

"@infodexx @spectatorindex Port-au-Prince has to be no 1"
X Link 2025-08-18T20:37Z [--] followers, [--] engagements

"$VKTX This is the first time the market has punished Viking for a result in a clinical trial in obesity. All VK2735 previous trials had been overwhelming successes"
X Link 2025-08-19T20:35Z [--] followers, [---] engagements

"@davidstehle Its just a guess on your part- this inference you are making"
X Link 2025-08-27T00:44Z [--] followers, [--] engagements

"@davidstehle You sound very sure of yourself but have not spent a minute in that household"
X Link 2025-08-27T01:09Z [--] followers, [--] engagements

"$ATYR Ive reduced my position and intend to do more of that and go down to 50% of my original holding"
X Link 2025-09-02T14:27Z [--] followers, [---] engagements

"@hannibalspeaks @seedy19tron I'm not saying he isn't right. just seems most shorts are super confident. The ph2b didn't provide much data so I cannot understand how anybody can come up with a rational conclusion based on that. Ph3 is a completely different trial (size length inclusion criteria PE)"
X Link 2025-09-05T08:30Z [--] followers, [--] engagements

"@TennisTV @carlosalcaraz Borg retiring so young is the thing that also stands out"
X Link 2025-09-06T15:57Z [--] followers, [---] engagements

"@epickram Its ph2a but prop xene had $2B + valuation after their ph2"
X Link 2025-09-08T12:17Z [--] followers, [---] engagements

"@atptour @usopen Slice backhand nice I guess he changed it up and Sinner was not able to deal with it. Reminds me of the Dimitrov match at Wimbledon"
X Link 2025-09-08T15:56Z [--] followers, [--] engagements

"@SiriusStarCapi1 So someone is buying the slack / majorly increasing position before readout"
X Link 2025-09-12T03:33Z [--] followers, [--] engagements

"$ATYR best case scenario for me personally is that on Friday they announce for data release on Monday [--] ;) I have no options"
X Link 2025-09-15T10:20Z [--] followers, [---] engagements

"@ElMonoGran42994 I think the immunosuppressant background therapy (39% of study participants were on that) might also have played a role. Plus doctors as many shorts correctly assessed were overprescribing OCS and doing so stubbornly and for too long"
X Link 2025-09-15T15:46Z [--] followers, [--] engagements

"@Biohazard3737 Its not really cancel culture anymore but something far worse"
X Link 2025-09-18T05:50Z [--] followers, [---] engagements

"@Godgivingtree @seedy19tron Check market cap Up is relative"
X Link 2025-09-25T00:20Z [--] followers, [--] engagements

"$OVID negative sentiment spreading to this ticker too after terrible readouts this morning"
X Link 2025-09-29T13:38Z [--] followers, [---] engagements

"@houndcl makes sense. elegant solution theoretically. Let's hope the MAD shows it works"
X Link 2025-09-30T08:50Z [--] followers, [--] engagements

"@houndcl also given the terrible tox and black box warning for VGB I wonder what will be the acceptable safety threshold for OV329"
X Link 2025-09-30T08:52Z [--] followers, [--] engagements

"@josemorgado Weird that for so many matches it was half empty"
X Link 2025-10-01T08:06Z [--] followers, [---] engagements

"@RnaudBertrand @Sandgropper2 I guess it indirectly validates $CAPR Deramiocel"
X Link 2025-10-06T06:01Z [--] followers, [----] engagements

"@CypherdC @MeadowCapital @trentkelp Agreed. They need a catalyst to bring the SP up. What happened to [----] which is essentially ph3 & partnership ready Maybe the IND for amylin candidate can give SP a small bump Strange that the MTSR buyout didnt bring price much higher- also because of scarcity"
X Link 2025-10-07T04:33Z [--] followers, [--] engagements

"@smiuffy I did buy a few shares yesterday"
X Link 2025-10-10T13:35Z [--] followers, [--] engagements

"@PersimmonTI Why would they buy $NAMS when ESPR is much lower valuation with no risk"
X Link 2025-10-13T16:12Z [--] followers, [---] engagements

"@doepke_michel Or JnJ and Actelion"
X Link 2025-10-13T22:15Z [--] followers, [--] engagements

"@AndreaRilli @masonat7 @financebully @PersimmonTI @EspR Company valuation just $600M compared to $4B plus for $NAMS"
X Link 2025-10-14T07:57Z [--] followers, [---] engagements

"@financebully @AndreaRilli @masonat7 @PersimmonTI @EspR this will position BA as a key therapeutic for heart disease"
X Link 2025-10-14T09:37Z [--] followers, [--] engagements

"#microplastics Petrostates and the plastics industry have argued the focus should be on recycling plastic not cutting production. But unlike paper glass steel and aluminium chemically complex plastics cannot be readily recycled. Shameless https://www.theguardian.com/environment/2025/aug/03/world-in-15tn-plastics-crisis-hitting-health-from-infancy-to-old-age-report-warns https://www.theguardian.com/environment/2025/aug/03/world-in-15tn-plastics-crisis-hitting-health-from-infancy-to-old-age-report-warns"
X Link 2025-08-03T23:10Z [--] followers, [---] engagements

"$OVID readout at end of September. Has had a great run so farfrom around $20M market cap to just shy of $100M. What was the valuation of $XENE after their successful azetukalner ph1b"
X Link 2025-09-03T20:08Z [--] followers, [----] engagements

"@monaco_biotech @Sanctuary_Bio @avidresearch @encodelp I was in xene at the very start (before they validated 1101) and this program by Ovid reminded me of that story - was fun to the see that same parallel drawn by Encode. However data for $OVID is still missing. Lets see"
X Link 2025-09-26T14:50Z [--] followers, [---] engagements

"$OVID finish this sentence: some cos preannounce others"
X Link 2025-10-01T12:24Z [--] followers, [----] engagements

"$OVID fantastic presentation. Meg Alexander rocks"
X Link 2025-10-03T13:37Z [--] followers, [----] engagements

"$OVID seems many oblivious to upcoming KCC2 ph1 readout (weeks away). plus next year should be rich in regulatory catalysts and why not a partnership for KCC2 program (they have a large portfolio of pre-clinical KCC2 activators & stated many times that partnerships were welcome)"
X Link 2025-10-03T17:26Z [--] followers, [----] engagements

"@smiuffy Orano results for same kinda alpha emitter https://www.fiercebiotech.com/biotech/sanofis-110m-radioligand-therapy-hits-response-rate-goal-phase-2-tumor-trial https://www.fiercebiotech.com/biotech/sanofis-110m-radioligand-therapy-hits-response-rate-goal-phase-2-tumor-trial"
X Link 2025-10-09T13:27Z [--] followers, [--] engagements

"$CATX seems undervalued. BTIG just came out with $14 target. Plus $SNY & Orano Med just demonstrated 212pb (alpha emitter) works"
X Link 2025-10-10T13:34Z [--] followers, [----] engagements

"Good take on $OVID being undervalued (compared to peers). EV after PIPE dilution and cash infusion just $110M"
X Link 2025-10-10T13:41Z [--] followers, [---] engagements

"@PersimmonTI @Nature $Catx nice to see SP continue to rise. Imo the CEO is very good (very articulate/ straightforward in the EC and investor presentations I listened to). Not sure what their status is with LNTH partnership I guess will depend on readouts"
X Link 2025-10-13T13:44Z [--] followers, [---] engagements

"$PTGX any other bidders besides JnJ"
X Link 2025-10-13T16:15Z [--] followers, [---] engagements

"$HYPR does it count as an AI play The Swoop is embedding AI into a mobile nimble head & brain MRI tech that can be wheeled to the patients bedside. Early stages but promising and likely a trend that will sweep through & bring innovation to med tech products"
X Link 2025-10-16T11:18Z [--] followers, [---] engagements

"$PRAX wow. Good on the company to not discontinue studies and keep the faith. Few saw this coming. (I have no position)"
X Link 2025-10-16T11:26Z [--] followers, [---] engagements

"@AnnaK_4ever Or they lost the cup"
X Link 2025-10-20T12:34Z [--] followers, [---] engagements

"@hiroyt100 @AnnaK_4ever Soderling Maybe that one run"
X Link 2025-10-20T12:41Z [--] followers, [--] engagements

"$qure seems Prasad lives in a bubble or ivory tower"
X Link 2025-11-03T12:44Z [--] followers, [---] engagements

"@adamfeuerstein @A_May_MD This is good for $vktx longs. Validates CEOs very high valuation which is the only reason Viking is still independent"
X Link 2025-11-04T20:18Z [--] followers, [---] engagements

"$MTSR was trading around $35 ($3.8B valuation) before the PFE BO offer was announced. $NVO just tabled a $10B offer"
X Link 2025-11-04T20:35Z [--] followers, [---] engagements

"$MTSR $PFE $NVO as LLY has shown the most effective drug wins out. Not sure what NVO & PFE have seen that suggest MTSR drugs will top TZP. Is it for oral programs"
X Link 2025-11-04T20:44Z [--] followers, [---] engagements

"@avidresearch $DRUG just entered the space but its a long they will initiate ph1 next year. BMB 5-HT2C agonists to be the first on-target mechanism addressing both neuropsychiatric symptoms and hyperphagia"
X Link 2025-11-10T21:11Z [--] followers, [---] engagements

"@bioinvestor24 I guess the $VKTX platform is all about dualitySQ & ORAL with same compound whic could provide differentiation & competitive advantage in terms of clinical development & commercial"
X Link 2025-11-13T13:01Z [--] followers, [---] engagements

"@bioinvestor24 Yes. Also I feel this duality oral/SQ is something thats been very overlooked. Upcoming regulatory updates (and maintenance trials) could really make that differentiator clear for everyone"
X Link 2025-11-13T13:25Z [--] followers, [--] engagements

"@bioinvestor24 Yeah seems its one of the most predictable drugs from ph2 to ph3 another reason why this feels like a no-brainer compared to other biotechs"
X Link 2025-11-14T20:39Z [--] followers, [--] engagements

"@bioinvestor24 @ManOnThePen Did they really ignore GIP I thought they eventually tried to develop a dual agonist but failed miserably"
X Link 2025-11-20T07:57Z [--] followers, [--] engagements

"@seedy19tron Sorry that sucks. I was long but small position - I decreased it over time to edge and be safer after the $ATYR loss. But always thought that shorting CAPR was shocking given potential upside of the stock with positive readout"
X Link 2025-12-03T13:48Z [--] followers, [---] engagements

"@seedy19tron Are you going to reconsider $VKTX given obesity scarcity potential best-in-class and management execution so far Also incretins in general one of the safest ph2 to ph3 (consistency predictability of results) imo"
X Link 2025-12-05T19:54Z [--] followers, [----] engagements

"$DRUG what happened $80"
X Link 2025-12-05T22:34Z [--] followers, [--] engagements

"$LLY seems market focusing on weight loss - not AEs or rate of discontinuation I guess easier to give a pass (or reward) a Lily than unproven clinical-stage biotechs such as $VKTX"
X Link 2025-12-11T12:58Z [--] followers, [---] engagements

"$OVID imagine many of those taking Incretins from $LLY and $NVO have to deal with nausea and vomiting. The KCC2 activators will be targeting serious neurological diseases"
X Link 2025-12-18T15:00Z [--] followers, [---] engagements

"Great piece in NYT-people sharing personal experience taking GLP-1 drugs $LLY $NVO $VKTX $MTSR Low dose maintenance may be whats needed once Wt target is achieved. IMO Viking leading the way with low-dose / low-frequency maintenance trial https://www.nytimes.com/interactive/2025/12/18/opinion/focus-group-former-glp1.html https://www.nytimes.com/interactive/2025/12/18/opinion/focus-group-former-glp1.html"
X Link 2025-12-19T09:00Z [--] followers, [---] engagements

"$OVID [----] should be rich in catalyst and milestones. Starting with Meg Alexander taking over as CEO on Jan [--]. OV350 Ph1 results open the door for Ovids entire KCC2 activator library to become clinical-stage assets. The company plans to IND one activator/year"
X Link 2025-12-19T09:37Z [--] followers, [---] engagements

"$OVID nice move up 20%"
X Link 2025-12-22T20:11Z [--] followers, [---] engagements

"@Biotech2k1 Seems CNS has been put on the back burner by most big pharma though things are changing ABBV could be one interested in beefing up (after the CERE bomb) CNS then theres $BMY $JNJ and I think thats about it maybe $LLY & ROCHE so actually quite a few"
X Link 2026-01-02T22:45Z [--] followers, [---] engagements

"@monaco_biotech Whats your prediction for tomorrow"
X Link 2026-01-05T22:04Z [--] followers, [---] engagements

"@Biotech2k1 $OVID"
X Link 2026-01-07T00:11Z [--] followers, [----] engagements

"@DannyDrinksWine Dancer in the Dark"
X Link 2026-01-08T22:57Z [--] followers, [---] engagements

"$XENE OLE data: 38% achieving one year seizure freedom quite impressive. This for DRE. Wonder if peak revenues will dwarf what most analysts predict https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-showcases-new-48-month-azetukalner-ole-study-data-epilepsy https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-showcases-new-48-month-azetukalner-ole-study-data-epilepsy"
X Link 2025-12-05T23:44Z [--] followers, [---] engagements

"$VKTX imo what the market is missing is that obesity drugs by $LLY & $NVO are now a massive consumer-driven market. In such markets the best products tend to win. Even more so in the wellness market. If VK2735 is indeed a superior product it will become market leader"
X Link 2025-12-22T22:04Z [--] followers, [----] engagements

"$VKTX keeps executing. Its easier to do so when you have a fantastic molecule & most people arententirely satisfied with whats commercially available - even $LLY drug can be improved upon. Just look whats happening to $NVO since TZP was introduced. Best drug wins"
X Link 2025-11-19T13:04Z [--] followers, 14.6K engagements

"$DRUG anecdotal: two patients in trial were obese and lost significant weight without nausea or vomit bodes well for PWS ph1 trial. Weight loss was behavioral"
X Link 2026-01-06T14:09Z [--] followers, [---] engagements

"@seedy19tron $DRUG CEO is def weird I notice how on the about us / leadership page he is at the bottom - seems he is more of a liability than an asset. Fortunately scientific team seems legit. Re $LBPH windfall - that was a strike of luck but also reward for their fortitude and ingenuity"
X Link 2025-07-02T12:07Z [--] followers, [---] engagements

"@Bionavgator But then why fly to Paris where $ABVX is based Why not choose a neutral site that is not Denmark or Paris If indeed $ASND is another candidate"
X Link 2025-12-11T11:49Z [--] followers, [----] engagements

"@idalopirdine @E_McClintock_ $DRUG are using firefly RNS to measure external EEG & capture seizure and brain data - $RAPP I believe used RNS (electrodes). Both using these techs as to provide some objective proof drugs work. Of course jury for [---] is still out"
X Link 2025-12-11T20:40Z [--] followers, [---] engagements

"@sharkbiotech Finally someone talks about $XENE yeah not sure how much market cap could move. Recent OLE results were impressive: 38% of patients treated for [--] months achieved [--] or more consecutive months of seizure freedom"
X Link 2025-12-19T20:59Z [--] followers, [---] engagements

"@Biotech2k1 Yeah but who would buy $PRAX And for how much Seems they are better off going alone. $XENE if ph3 hits seems like an easier BO for a big pharma though their pain pipeline is a wild card until ph1 readouts"
X Link 2026-01-02T22:29Z [--] followers, [---] engagements

"$DRUG the no-trip psychedelic drug-developer that most psychedelic drug retail investors seem to overlook Sorry that was a mouthful $cybn $atai $mnmd"
X Link 2026-01-03T17:02Z [--] followers, [---] engagements

"$XENE $DRUG later this week"
X Link 2026-01-05T20:19Z [--] followers, [---] engagements

"$ESPR as ACC and ESC now rank hsCRP as the superior predictor of heart attacks (over LDL) [----] may be the year ESPR finally lives up to its potential: BA uniquely targets inflammation and bad cholesterol"
X Link 2026-01-05T20:51Z [--] followers, [---] engagements

"$DRUG this seems really good REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep duration"
X Link 2026-01-06T12:26Z [--] followers, [---] engagements

"Yeah On the money Guys it's possible $ABBV lost $RVMD to someone else or else talks just fell apart We shall see But no chance WSJ pulled a betaville here Guys it's possible $ABBV lost $RVMD to someone else or else talks just fell apart We shall see But no chance WSJ pulled a betaville here"
X Link 2026-01-08T21:35Z [--] followers, [--] engagements

"$XENE so now ph3 readout pushed to march When they had guided to very early Q1 / start of year not long ago They keep pushing back its been a little annoying and not a good look by management imo"
X Link 2026-01-13T21:35Z [--] followers, [---] engagements

"@PersimmonTI What about $ESPR"
X Link 2026-02-01T14:44Z [--] followers, [---] engagements

"@JoseRestonVA Since you are in NAMS have you ever considered ESPR Seems major catalysts taking place in 2026-27 - with ACC guidelines update discovery that it locks into ppar alpha and triple combo drug launch in 2027"
X Link 2026-02-01T14:48Z [--] followers, [--] engagements

"@A_May_MD Quite important: LLY is dual agonist (GLP-1 & GIP) drug profile & benefits over GLP-1 explains everything. Sorry to be annoying about that difference ;)"
X Link 2026-02-04T15:01Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing